INTSMEDIUM SIGNALFINANCIAL10-K

INTS executed a 1-for-25 reverse stock split while significantly improving its cash position from $2.6M to $11.9M and reducing R&D spending by 35%.

The reverse stock split typically signals management's attempt to boost share price to meet exchange listing requirements or attract institutional investors, though it reduces the share count from ~15.2M to 2.5M shares. The substantial cash increase suggests successful fundraising that should extend the company's runway, while the reduced R&D spending could indicate either cost discipline or scaling back of research activities.

Comparing 2026-03-27 vs 2025-03-13View on EDGAR →
FINANCIAL ANALYSIS

The company's financial position strengthened considerably with cash increasing 360% to $11.9M and total assets nearly doubling to $14.1M, likely from equity fundraising. Operating performance improved with R&D expenses declining 35% and net losses narrowing from -$16.3M to -$11.6M, while operating cash flow burn reduced by 39% to -$9.2M. The overall picture suggests improved financial stability and extended operational runway, though the reverse stock split indicates prior share price pressures.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
+360.3%
$2.6M$11.9M

Cash position surged 360.3% — strong cash generation or capital raise providing significant financial cushion.

Stockholders Equity
Balance Sheet
+307%
$2.9M$11.9M

Equity base grew 307% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Current Assets
Balance Sheet
+277.9%
$3.4M$12.7M

Current assets grew 277.9% — improving short-term liquidity or inventory/receivables build.

Interest Expense
P&L
+272%
$82K$305K

Interest expense surged 272% — significant debt increase or rising rates materially impacting earnings.

Total Assets
Balance Sheet
+194.8%
$4.8M$14.1M

Asset base grew 194.8% — expansion through organic growth, acquisitions, or capital deployment.

Operating Cash Flow
Cash Flow
+39.3%
-$15.2M-$9.2M

Operating cash flow surged 39.3% — exceptional cash generation, highest quality earnings signal.

R&D Expense
P&L
-35.4%
$10.5M$6.8M

R&D spending cut 35.4% — could signal cost discipline or concerning reduction in innovation investment.

Net Income
P&L
+28.7%
-$16.3M-$11.6M

Net income grew 28.7% — bottom-line growth signals improving overall business health.

Operating Income
P&L
+27.8%
-$16.6M-$12.0M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Current Liabilities
Balance Sheet
+22.3%
$1.8M$2.1M

Current liabilities rose 22.3% — increased short-term obligations, watch current ratio.

LANGUAGE CHANGES
NEW — 2026-03-27
PRIOR — 2025-03-13
ADDED
As o f March 26, 2026, the registrant had 2,540,518 shares o f common stock, $0.0001 par value, outstanding.
On February 19, 2026, we effected a 1-for-25 reverse stock split of our common stock (the Reverse Stock Split ).
All historical share and per share amounts reflected throughout this Annual Report on Form 10-K have been adjusted to reflect the Reverse Stock Split.
The challenge with IT treatment approaches is that a tumor s stromal, high-fat, dense, poorly vascularized, and pressurized microenvironment is incompatible with and does not absorb water-based products.
We believe that this drug delivery challenge limits the effectiveness of prior and current IT treatments, which have involved injecting aqueous drugs into a tumor without sufficient consideration of the tumor environment.
+7 more — sign up free →
REMOVED
As o f March 12, 2025, the registrant had 15,180,945 shares o f common stock, $0.0001 par value, outstanding.
The challenge with IT treatment approaches is that a tumor s lipophilic, high fat, dense and pressurized microenvironment is incompatible with and does not absorb water-based products.
We believe that this drug delivery challenge limits the effectiveness of prior and current IT treatments, which involve injecting aqueous drugs into a tumor without sufficient consideration of the tumor environment (regardless of the drug s mechanism or approach, i.e.
We believe we have created a product candidate with the necessary chemistry to overcome this local delivery challenge.
We also sought to determine whether a local or whole-body anti-cancer immune response could be induced.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →